Cellular delivery of antisense oligonucleotides.

Antisense oligonucleotides can be successfully employed to inhibit specifically gene expression. However, many oligonucleotide classes are polyanions and cannot passively transit the cell membrane. Thus, the use of naked oligonucleotides for antisense purposes poses some rather stringent challenges, and it is not a trivial task to appropriately interpret the data derived from experiments in which they have been used. Multiple methods have been developed to improve intracellular, and in particular, intranuclear oligonucleotide delivery, and in doing so, to maximize the performance of the antisense technologies that are currently available. This review discusses the use of cationic lipids, protein and peptide delivery agents, and several novel chemical and viral methods that have recently been explored as delivery vehicles, focussing not only on their strengths, but also on their limitations.

[1]  C. Steer,et al.  Nucleotide Exchange in Genomic DNA of Rat Hepatocytes Using RNA/DNA Oligonucleotides , 1999, The Journal of Biological Chemistry.

[2]  V. Soldatenkov,et al.  Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer , 1997, Gene Therapy.

[3]  P. D. Cook,et al.  In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. , 1997, Nucleic acids research.

[4]  T. Ogihara,et al.  Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. , 1994, Gene.

[5]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[6]  P. Cheng,et al.  Lectin conjugate-directed gene transfer to airway epithelial cells. , 1994, Biochemical and biophysical research communications.

[7]  A. Gewirtz,et al.  Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. , 1995, The Journal of clinical investigation.

[8]  A. Kabanov,et al.  Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. , 1998, Bioconjugate chemistry.

[9]  F. Gasparro,et al.  CELL MEMBRANE DNA: A NEW TARGET FOR PSORALEN PHOTOADDUCT FORMATION , 1990, Photochemistry and photobiology.

[10]  A. Zimmer,et al.  Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides. , 1997, Antisense & nucleic acid drug development.

[11]  S. Akhtar,et al.  Antisense technology: selection and delivery of optimally acting antisense oligonucleotides. , 1998, Journal of drug targeting.

[12]  H. Blum,et al.  Antisense therapy of hepatitis B virus infection , 1998, Molecular biotechnology.

[13]  M. Bassik,et al.  DNA vector chemistry: The covalent attachment of signal peptides to plasmid DNA , 1998, Nature Biotechnology.

[14]  H. Iishi,et al.  In vivo electroporetic transfer of bcl‐2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats , 2000, International journal of cancer.

[15]  C. Hélène,et al.  Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles. , 1995, European Journal of Biochemistry.

[16]  A. Dritschilo,et al.  Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. , 1992, Nucleic acids research.

[17]  J. Loike,et al.  Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein , 1997, Nature Medicine.

[18]  P. Nielsen,et al.  Progress in developing PNA as a gene-targeted drug. , 1997, Antisense & nucleic acid drug development.

[19]  J. C. Perales,et al.  Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Morishita,et al.  DNA transfer into vascular smooth muscle using fusigenic Sendai virus (HJV)-liposomes , 1997 .

[21]  Y. Kaneda,et al.  Fusigenic viral liposome for gene therapy in cardiovascular diseases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Madon,et al.  Receptor‐mediated delivery of hepatitis B virus DNA and antisense oligodeoxynucleotides to avian liver cells , 1996, Hepatology.

[23]  A. Frankel,et al.  Endocytosis and targeting of exogenous HIV‐1 Tat protein. , 1991, The EMBO journal.

[24]  D. Ma,et al.  Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. , 1996, Leukemia research.

[25]  B. Sikic,et al.  Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  J. M. Brown,et al.  Fate of cationic liposomes and their complex with oligonucleotide in vivo. , 1996, Biochimica et biophysica acta.

[27]  S. Simões,et al.  Gene delivery mediated by cationic liposomes: from biophysical aspects to enhancement of transfection. , 1999, Molecular membrane biology.

[28]  K. Stecker,et al.  An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. , 1997, The Journal of pharmacology and experimental therapeutics.

[29]  Joseph Zabner,et al.  Cellular and Molecular Barriers to Gene Transfer by a Cationic Lipid (*) , 1995, The Journal of Biological Chemistry.

[30]  A. Kabanov,et al.  Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides , 1999, Nature Biotechnology.

[31]  T. Allen,et al.  A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. , 1995, Biochimica et biophysica acta.

[32]  S. Simões,et al.  Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. , 1999, Molecular membrane biology.

[33]  D. Ecker,et al.  Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. , 1992, The Journal of biological chemistry.

[34]  P. Couvreur,et al.  Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[35]  M. Yarmush,et al.  Covalent protein-oligonucleotide conjugates for efficient delivery of antisense molecules. , 1997, Bioconjugate chemistry.

[36]  W. Wels,et al.  Target Cell-specific DNA Transfer Mediated by a Chimeric Multidomain Protein , 1996, The Journal of Biological Chemistry.

[37]  J. Fréchet,et al.  Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy. , 1994, Science.

[38]  E. Nabel,et al.  Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. , 1992, Human gene therapy.

[39]  A. Gabizon,et al.  Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. , 1990, Cancer research.

[40]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[41]  J. Behr,et al.  Liver‐directed gene transfer: a linear polyethylenimine derivative mediates highly efficient DNA delivery to primary hepatocytes in vitro and in vivo , 1998, Journal of viral hepatitis.

[42]  W. Pardridge,et al.  Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Corey,et al.  Cellular delivery of peptide nucleic acids and inhibition of human telomerase. , 1999, Chemistry & biology.

[44]  W. Flanagan,et al.  A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Matsuno,et al.  In vitro and in vivo delivery of antisense oligodeoxynucleotides using lipofection: application of antisense technique to growth suppression of experimental glioma. , 2000, Methods in enzymology.

[46]  A. Periasamy,et al.  Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. , 1991, Nucleic acids research.

[47]  G. Gregoriadis,et al.  Biodistribution, stability, and antiviral efficacy of liposome‐entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection , 1998, Hepatology.

[48]  S. Simões,et al.  Sterically Stabilized pH-sensitive Liposomes , 1997, The Journal of Biological Chemistry.

[49]  M. Monsigny,et al.  Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide. , 1997, Antisense & nucleic acid drug development.

[50]  B. Calabretta,et al.  Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. , 1994, British Journal of Cancer.

[51]  F. Szoka,et al.  Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. , 1998, Biochimica et biophysica acta.

[52]  P. Ross,et al.  Lipoplex size is a major determinant of in vitro lipofection efficiency , 1999, Gene Therapy.

[53]  J. C. Martin,et al.  Current concepts in antisense drug design. , 1993, Journal of medicinal chemistry.

[54]  John W. Park,et al.  Cationic Liposomes Coated with Polyethylene Glycol As Carriers for Oligonucleotides* , 1998, The Journal of Biological Chemistry.

[55]  H. Pehamberger,et al.  bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice , 1998, Nature Medicine.

[56]  G. Zon,et al.  Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. , 1994, Nucleic acids research.

[57]  R. Kumar,et al.  Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. , 1994, The Journal of biological chemistry.

[58]  P. Low,et al.  Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[59]  A. Kabanov,et al.  Polyion complex micelles with protein-modified corona for receptor-mediated delivery of oligonucleotides into cells. , 1999, Bioconjugate chemistry.

[60]  H. D. Liggitt,et al.  Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery , 1997, Nature Biotechnology.

[61]  L. Huang,et al.  Plasmid DNA adsorbed to pH-sensitive liposomes efficiently transforms the target cells. , 1987, Biochemical and biophysical research communications.

[62]  T. Abe,et al.  Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A , 1999, Nature Biotechnology.

[63]  F. Szoka,et al.  Mechanism of oligonucleotide release from cationic liposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. C. Perales,et al.  Receptor-mediated gene transfer into macrophages. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[65]  M. Cotten,et al.  Transferrin-polycation conjugates as carriers for DNA uptake into cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[66]  M. Andreeff,et al.  Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides , 1996, Journal of Molecular Medicine.

[67]  S. Freier,et al.  Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. , 1991, The Journal of biological chemistry.

[68]  A. Zimmer,et al.  Use of liposomes, viral capsids, and nanoparticles as DNA carriers , 1991, Biotechnology and applied biochemistry.

[69]  Y. Nagasaki,et al.  Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(D,L-lactide) block copolymers as potential drug carrier. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[70]  Doriano Fabbro,et al.  Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase , 1996, Nature Medicine.

[71]  C. Wu,et al.  Receptor-mediated gene delivery and expression in vivo. , 1988, The Journal of biological chemistry.

[72]  F. Szoka,et al.  How are nucleic acids released in cells from cationic lipid-nucleic acid complexes? , 1997 .

[73]  W. Pardridge,et al.  Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. , 1998, Journal of pharmaceutical sciences.

[74]  J. C. Roberts,et al.  Using starburst dendrimers as linker molecules to radiolabel antibodies. , 1990, Bioconjugate chemistry.

[75]  L. Chaloin,et al.  Conformations of primary amphipathic carrier peptides in membrane mimicking environments. , 1997, Biochemistry.

[76]  H. Strey,et al.  Improved DNA: liposome complexes for increased systemic delivery and gene expression , 1997, Nature Biotechnology.

[77]  B. Calabretta,et al.  An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[78]  L. Miraglia,et al.  Characterization of a Potent and Specific Class of Antisense Oligonucleotide Inhibitor of Human Protein Kinase C-α Expression* , 1999, The Journal of Biological Chemistry.

[79]  N M Dean,et al.  Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. , 1998, Nucleic acids research.

[80]  P. Courtoy,et al.  Intracellular routing and inhibitory activity of oligonucleopeptides containing a KDEL motif. , 1997, Molecular pharmacology.

[81]  D. Fabbro,et al.  Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. , 1997, Journal of the National Cancer Institute.

[82]  L. Chaloin,et al.  A novel potent strategy for gene delivery using a single peptide vector as a carrier. , 1999, Nucleic acids research.

[83]  M. Hope,et al.  Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review). , 1998, Molecular membrane biology.

[84]  D. Papahadjopoulos,et al.  Stabilization of cationic liposome‐plasmid DNA complexes by polyamines and poly(ethylene glycol)‐phospholipid conjugates for efficient in vivo gene delivery , 1997, FEBS letters.

[85]  F. Szoka,et al.  Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. , 1993, Bioconjugate chemistry.

[86]  M. Fresta,et al.  Liposomal delivery of a 30-mer antisense oligodeoxynucleotide to inhibit proopiomelanocortin expression. , 1998, Journal of pharmaceutical sciences.

[87]  D. Wielbo,et al.  Antisense inhibition of angiotensinogen in hepatoma cell culture is enhanced by cationic liposome delivery. , 1997, Biochemical and biophysical research communications.

[88]  J Barsoum,et al.  Tat-mediated delivery of heterologous proteins into cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[89]  P. Berg,et al.  Rapid renaturation of complementary DNA strands mediated by cationic detergents: a role for high-probability binding domains in enhancing the kinetics of molecular assembly processes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[90]  L. Chaloin,et al.  A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. , 1997, Nucleic acids research.

[91]  M. Hashida,et al.  Development of targeted delivery systems for nucleic acid drugs. , 1997, Journal of drug targeting.

[92]  L. Chaloin,et al.  Interactions of Primary Amphipathic Vector Peptides with Membranes. Conformational Consequences and Influence on Cellular Localization , 1998, The Journal of Membrane Biology.

[93]  B. Davidson,et al.  Complexes of Adenovirus with Polycationic Polymers and Cationic Lipids Increase the Efficiency of Gene Transfer in Vitro and in Vivo* , 1997, The Journal of Biological Chemistry.

[94]  E. Nabel,et al.  Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[95]  P. Low,et al.  Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. , 1994, The Journal of biological chemistry.

[96]  Xiang Gao,et al.  Cationic liposome-mediated gene transfer. , 1995, Gene therapy.

[97]  R. Duff,et al.  Intrabody tissue-specific delivery of antisense conjugates in animals: ligand-linker-antisense oligomer conjugates. , 2000, Methods in enzymology.

[98]  M. Ariatti,et al.  Evidence for targeted gene transfer by receptor-mediated endocytosis. Stable expression following insulin-directed entry of NEO into HepG2 cells. , 1990, Biochemical pharmacology.

[99]  T. Ogihara,et al.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[100]  D Needham,et al.  Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. , 1993, Cancer research.

[101]  J. Frost,et al.  Tissue distribution and metabolism of the [32P]-labeled oligodeoxynucleoside methylphosphonate-neoglycopeptide conjugate, [YEE(ah-GalNAc)3]-SMCC-AET-pUmpT7, in the mouse. , 1997, Antisense & nucleic acid drug development.

[102]  C. Hélène,et al.  Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[103]  B. Monia,et al.  Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation. , 1997, Molecular pharmacology.

[104]  C. Hunt,et al.  Antisense c-myc oligonucleotide cellular uptake and activity. , 1994, Antisense research and development.

[105]  B. Froehler,et al.  Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. , 1995, Biochemistry.

[106]  A. Thierry,et al.  Characterization of liposome-mediated gene delivery: expression, stability and pharmacokinetics of plasmid DNA , 1997, Gene Therapy.

[107]  G. Zon,et al.  Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. , 1993, Antisense research and development.

[108]  R. Juliano,et al.  Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. , 1997, Journal of pharmaceutical sciences.

[109]  R. Wagner.  Gene inhibition using antisense oligodeoxynucleotides , 1994, Nature.

[110]  K. Jayaraman,et al.  Novel Polyaminolipids Enhance the Cellular Uptake of Oligonucleotides (*) , 1995, The Journal of Biological Chemistry.

[111]  F. Szoka,et al.  Association of a pH-sensitive peptide with membrane vesicles: role of amino acid sequence. , 1990, Biochemistry.

[112]  J. Hughes,et al.  In vitro transport and delivery of antisense oligonucleotides. , 2000, Methods in enzymology.

[113]  R. Smith.  The pathobiology of HIV infection. A review. , 1990, Archives of pathology & laboratory medicine.

[114]  C. Stein,et al.  Patterns of intracellular compartmentalization, trafficking and acidification of 5'-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. , 1994, Nucleic acids research.

[115]  E. Kyle,et al.  Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. , 1996, Blood.

[116]  P. Martiat,et al.  Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. , 1997, Blood.

[117]  A. Frankel,et al.  Increased cellular uptake of the human immunodeficiency virus-1 Tat protein after modification with biotin. , 1995, Analytical biochemistry.

[118]  J. Baker,et al.  Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[119]  T. V. van Berkel,et al.  Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. , 1999, The Biochemical journal.

[120]  P. Nielsen,et al.  Cellular uptake of adamantyl conjugated peptide nucleic acids. , 1999, Bioconjugate chemistry.

[121]  M. Hope,et al.  Contact hypersensitivity: a simple model for the characterization of disease-site targeting by liposomes. , 1999, Biochimica et biophysica acta.

[122]  C. Bennett,et al.  Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. , 1992, Molecular pharmacology.

[123]  P. Davis,et al.  Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor. , 1993, The Journal of clinical investigation.

[124]  Y. Kaneda,et al.  In vivo delivery of phosphorothioate oligonucleotides into murine retina. , 1998, Archives of ophthalmology.

[125]  M. McCarthy.  Modulating Gene Expression by Antisense Oligonucleotides to Understand Neural Functioning , 2012, Perspectives in Antisense Science.

[126]  W. Pardridge,et al.  Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. , 1996, The Journal of pharmacology and experimental therapeutics.

[127]  David E Reichert,et al.  Self-Assembling Dendrimers , 1996, Science.

[128]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[129]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[130]  B. Lebleu,et al.  Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. , 1994, Nucleic acids research.

[131]  J. Kuiper,et al.  Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. , 1998, Molecular pharmacology.

[132]  J. Nyce,et al.  DNA antisense therapy for asthma in an animal model , 1997, Nature.

[133]  C. Bennett,et al.  Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity. , 2000, The Journal of pharmacology and experimental therapeutics.

[134]  W. Stec,et al.  Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of oligodeoxyribonucleotides , 1984 .

[135]  J. Baker,et al.  Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. , 1996, Nucleic acids research.

[136]  C. F. Bennett,et al.  The Role of Antiapoptotic Bcl-2 Family Members in Endothelial Apoptosis Elucidated with Antisense Oligonucleotides* , 1999, The Journal of Biological Chemistry.

[137]  M. Hashida,et al.  Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). , 1997, Biochemical pharmacology.

[138]  R. Rando,et al.  Inhibition of High Affinity Basic Fibroblast Growth Factor Binding by Oligonucleotides (*) , 1995, The Journal of Biological Chemistry.

[139]  G. Storm,et al.  Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. , 1992, Biochimica et biophysica acta.

[140]  Y. Cheng,et al.  Identification of two oligodeoxyribonucleotide binding proteins on plasma membranes of human cell lines. , 1996, Biochemical pharmacology.

[141]  P. Couvreur,et al.  Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. , 1999, Antisense & nucleic acid drug development.

[142]  E. Lesnik,et al.  Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[143]  L. Huang,et al.  Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. , 1995, Biochimica et biophysica acta.

[144]  K. Moelling,et al.  Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides , 1998, Journal of Molecular Medicine.

[145]  R. Juliano,et al.  Liposomes as a drug delivery system for antisense oligonucleotides. , 1992, Antisense research and development.

[146]  Lois E. H. Smith,et al.  Oligonucleotide-based inhibition of embryonic gene expression , 1999, Nature Biotechnology.

[147]  D. Spiller,et al.  Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. , 1995, Antisense research and development.

[148]  A. Deisseroth,et al.  Liposomal delivery of oligodeoxynucleotides. , 1996, Leukemia & lymphoma.

[149]  T. Torgerson,et al.  Inhibition of Nuclear Translocation of Transcription Factor NF-κB by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence (*) , 1995, The Journal of Biological Chemistry.

[150]  M. Aoki,et al.  In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method. , 1997, Biochemical and biophysical research communications.

[151]  A. Prochiantz,et al.  The third helix of the Antennapedia homeodomain translocates through biological membranes. , 1994, The Journal of biological chemistry.

[152]  T. Hökfelt,et al.  Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo , 1998, Nature Biotechnology.

[153]  P. Nielsen,et al.  Peptide nucleic acids (PNA): synthesis, properties and potential applications. , 1996, Bioorganic & medicinal chemistry.

[154]  S. Capaccioli,et al.  Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. , 1993, Biochemical and biophysical research communications.

[155]  W. Stec,et al.  Stereocontrolled Synthesis of Oligo(nucleoside phosphorothioate)s , 1994 .

[156]  S. Morrison,et al.  An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. , 1999, Journal of immunology.

[157]  L. Smith,et al.  Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression. , 1994, Gene therapy.

[158]  K. Koike,et al.  In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. , 1996, Biochemical and biophysical research communications.

[159]  G. Chaudhuri.  Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Selective and efficient elimination of the parasite. , 1997, Biochemical pharmacology.

[160]  G. Weissmann,et al.  Phospholipid spherules (liposomes) as a model for biological membranes. , 1968, Journal of lipid research.

[161]  G. Sczakiel,et al.  Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset. , 1998, Blood.

[162]  I. Gibson,et al.  Interaction of oligodeoxynucleotides with mammalian cells. , 1996, Antisense & nucleic acid drug development.

[163]  M. J. Martin,et al.  Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA , 1996, Antimicrobial agents and chemotherapy.

[164]  R. Gurny,et al.  Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[165]  E. Richelson,et al.  Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo , 1998, FEBS letters.

[166]  E. Waelti,et al.  Delivery to cancer cells of antisense L‐ myc oligonucleotides incorporated in fusogenic, cationic‐lipid‐reconstituted influenza‐virus envelopes (cationic virosomes) , 1998, International journal of cancer.

[167]  M. Bally,et al.  Generating and loading of liposomal systems for drug-delivery applications , 1989 .

[168]  J. Summerton,et al.  Morpholino antisense oligomers: design, preparation, and properties. , 1997, Antisense & nucleic acid drug development.

[169]  A. Tomida,et al.  Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. , 1998, Blood.

[170]  T Ochi,et al.  A comparison of in vivo gene delivery methods for antisense therapy in ligament healing , 1998, Gene Therapy.

[171]  S. Freier,et al.  Kinetics of G-quartet-mediated tetramer formation. , 1996, Biochemistry.

[172]  R. Ghirlando,et al.  Mode of formation and structural features of DNA-cationic liposome complexes used for transfection. , 1993, Biochemistry.

[173]  S. Agrawal,et al.  In vivo studies with antisense oligonucleotides. , 1997, Trends in pharmacological sciences.

[174]  L. Chaloin,et al.  Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties. , 1998, Biochemical and biophysical research communications.

[175]  L. Smith,et al.  Efficient nuclear delivery of antisense oligodeoxynucleotides and selective inhibition of CETP expression by apo E peptide in a human CETP-stably transfected CHO cell line. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[176]  F. Szoka,et al.  Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. , 1997, Biochemistry.

[177]  G. Storm,et al.  Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. , 1993, Biochimica et biophysica acta.

[178]  N. Dean,et al.  Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[179]  V. Vlassov,et al.  Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[180]  E. Wagner,et al.  Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes. , 1994, Antiviral research.

[181]  H. Farhood,et al.  The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. , 1995, Biochimica et biophysica acta.

[182]  C. L. Douglas,et al.  Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[183]  D. Fitzpatrick,et al.  Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. , 1996, Cancer research.

[184]  Joachim O. Rädler,et al.  Structure of DNA-Cationic Liposome Complexes: DNA Intercalation in Multilamellar Membranes in Distinct Interhelical Packing Regimes , 1997, Science.

[185]  M. Kamada,et al.  Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits* , 1998, The Journal of Biological Chemistry.

[186]  A. Prochiantz,et al.  Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent* , 1996, The Journal of Biological Chemistry.

[187]  P. Couvreur,et al.  Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. , 1992, Biochemical and biophysical research communications.

[188]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[189]  R. Wagner,et al.  Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. , 1993, Nucleic acids research.

[190]  M. Egholm,et al.  Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. , 1991, Science.

[191]  M. Findeis,et al.  Ligand-based carrier systems for delivery of DNA to hepatocytes. , 1994, Methods in enzymology.

[192]  L. Huang,et al.  Highly efficient DNA delivery mediated by pH-sensitive immunoliposomes. , 1989, Biochemistry.

[193]  K. Fisher,et al.  The transmembrane domain of diphtheria toxin improves molecular conjugate gene transfer. , 1997, The Biochemical journal.

[194]  C. F. Bennett,et al.  Progress in antisense oligonucleotide therapeutics. , 1996, Annual review of pharmacology and toxicology.

[195]  H. Hutchinson,et al.  Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[196]  S. Rotenberg,et al.  Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. , 1993, Biochemistry.

[197]  N. Dean,et al.  Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. , 1998, The Journal of pharmacology and experimental therapeutics.

[198]  W. Pardridge,et al.  Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[199]  J. Zweier,et al.  The natural polyamine spermine functions directly as a free radical scavenger. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[200]  A. Prochiantz,et al.  Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro , 1995, The Journal of cell biology.

[201]  R. Mayer,et al.  The nuclear export signal-dependent localization of oligonucleopeptides enhances the inhibition of the protein expression from a gene transcribed in cytosol , 1999, Nucleic Acids Res..

[202]  I. Wróbel,et al.  Fusion of cationic liposomes with mammalian cells occurs after endocytosis. , 1995, Biochimica et biophysica acta.

[203]  W. Stec,et al.  Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. , 1995, Nucleic acids research.

[204]  M. Watabe,et al.  Binding of oligonucleotides to cell membranes at acidic pH. , 1991, Biochemical and biophysical research communications.

[205]  E. Wickstrom,et al.  Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. , 1992, Cancer research.

[206]  R. Kole,et al.  Novel cationic amphiphiles as delivery agents for antisense oligonucleotides. , 1999, Nucleic acids research.

[207]  Wei Xin,et al.  Treatment of duck hepatitis B virus by antisense poly-2'-O-(2,4-dinitrophenyl)-oligoribonucleotides. , 1998, Antisense & nucleic acid drug development.

[208]  V V Demidov,et al.  Stability of peptide nucleic acids in human serum and cellular extracts. , 1994, Biochemical pharmacology.

[209]  L. Huang,et al.  DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. , 1994, Biochimica et biophysica acta.

[210]  G. Citro,et al.  Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. , 1997, Anticancer research.

[211]  A. Tari,et al.  Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. , 1999, The Journal of pharmacology and experimental therapeutics.

[212]  S. Crooke,et al.  In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. , 1995, The Journal of pharmacology and experimental therapeutics.

[213]  S. Akhtar.  Delivery strategies for antisense oligonucleotide therapeutics , 1995 .

[214]  B. Calabretta,et al.  A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. , 1988, Science.

[215]  M. Cotten,et al.  Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[216]  M. Yarmush,et al.  Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[217]  A. Zimmer,et al.  Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. , 1999, Methods.

[218]  Y. Cheng,et al.  Antisense oligonucleotides as therapeutic agents--is the bullet really magical? , 1993, Science.

[219]  Leaf Huang,et al.  Folate-targeted, Anionic Liposome-entrapped Polylysine-condensed DNA for Tumor Cell-specific Gene Transfer (*) , 1996, The Journal of Biological Chemistry.

[220]  N. Goldstein,et al.  Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[221]  I. D'Agnano,et al.  Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[222]  Pierre Vidal,et al.  Nouvelle stratégie pour vectorisation d'ARN dans des cellules de mammifères. Utilisation d'un vecteur peptidique , 1997 .

[223]  C. Stein,et al.  Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix (*) , 1995, The Journal of Biological Chemistry.

[224]  R. Crooke,et al.  Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture. , 1998, Journal of drug targeting.

[225]  B. Peng,et al.  Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles conjugated to ferric protoporphyrin IX (heme). , 1997, Antisense & nucleic acid drug development.

[226]  J. Pow-Sang,et al.  Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. , 1993, Cancer research.

[227]  P. Low,et al.  Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.